Automated vehicles are expected to enhance driving safety and comfort. In order to fulfil these expectations, they have to be widely accepted and used. Implementing an acceptable driving style is therefore a must. Previous research on automated vehicle acceptance has largely concentrated on the effects of driving dynamics. This study takes a different approach and focuses on the effects of the driving decisions. To assess the effects of driving decisions on acceptance, an online experimental study was conducted in China, Germany, Japan and the US. Four overtaking scenarios, in which the automated vehicle took a decision, were presented as short texts. The situations differed with regard to the action (overtaking vs. stay in lane) and potential consequence (high or low hindrance of another driver). Participants then rated their acceptance. The results indicate that acceptance is dependent on the driving decisions and is further influenced by cultural background. Chinese drivers show high acceptance to the decisions and there were no significant differences between the presented scenarios. In the US and Germany, decisions leading to high hindrance of others are rejected, whereas in cases of low hindrance, overtaking is preferred. Japanese participants reject decisions, which lead to hindrance of others.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.apergo.2020.103346 | DOI Listing |
Curr Treat Options Neurol
July 2024
Department of Neurology, Division of Behavioral Neurology, Stanford Neuroscience Health Center, 453 Quarry Road, Palo Alto, CA 94304, USA.
Purpose Of Review: The purpose of this review is to discuss the clinical, radiological, and neuropathological heterogeneity of corticobasal syndrome (CBS), which can complicate the determination of underlying etiology and lead to inaccurate treatment decisions. Though the most common diagnosis is corticobasal degeneration (CBD), the spectrum of underlying pathologies expands beyond CBD and can overlap with other neurodegenerative diseases and even the neuroimmunology field. We will review possible clinical presentations and cues that can point towards the etiology.
View Article and Find Full Text PDFChem Biomed Imaging
January 2025
Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana 47907, United States.
Due to uncontrolled cell proliferation and disrupted vascularization, many cancer cells in solid tumors have limited oxygen supply. The hypoxic microenvironments of tumors lead to metabolic reprogramming of cancer cells, contributing to therapy resistance and metastasis. To identify better targets for the effective removal of hypoxia-adaptive cancer cells, it is crucial to understand how cancer cells alter their metabolism in hypoxic conditions.
View Article and Find Full Text PDFBMJ Oncol
February 2024
Biosciences Institute, Newcastle University, Newcastle Upon Tyne, UK.
Cancer remains one of the most formidable challenges in modern medicine, due to its complex and dynamic nature, which demands innovative therapeutic approaches. One major challenge to cancer treatment is the tumour microenvironment and in particular tumour hypoxia (low oxygen levels), which contributes to tumour progression and immune evasion. At the cellular level, this is primarily governed by hypoxia-inducible factor (HIF).
View Article and Find Full Text PDFMetabol Open
March 2025
First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
Anemia is a frequent, yet increasingly recognized, comorbidity in diabetes mellitus (DM), with prevalence often driven by multifactorial mechanisms. Hematinic deficiencies, common in this population, may arise from associated comorbidities or medications, such as metformin, as well as other drugs commonly employed for DM-related conditions. Among contributing factors, diabetic kidney disease (DKD) plays a pivotal role, with anemia developing more frequently and being more pronounced in earlier stages, than in CKD of other causes.
View Article and Find Full Text PDFFront Immunol
January 2025
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria.
Background: The G protein-coupled receptor 55 (GPR55) is part of an expanded endocannabinoid system (ECS), and plays a pro-tumorigenic role in different cancer models, including pancreatic cancer. Next to cancer cells, various cells of the immune tumor microenvironment (TME) express receptors of the ECS that critically determine tumor growth. The role of GPR55 in cancer cells has been widely described, but its role in the immune TME is not well understood.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!